Pilot-study: Predicton of response on Lu177-radioligand therapy in metastatic prostate carcinoma by early serial PSA-value examination

Pilot-study: Predicton of response on Lu177-radioligand therapy in metastatic prostate carcinoma by early serial PSA-value examination - PCA-PSA-EPBR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00013500

Enrollment

Registered

2017-12-01

Start date

2017-02-02

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: On date of therapy and 1, 2, 3, 8 days after therapy PSA-serum values are determined and compared with the PSA-value 4 weeks after therapy.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Metastatic, castration refractory prostate carcinoma, Lu177-PSMA-617-radioligand therapy planned

Exclusion criteria

Exclusion criteria: No significant PSA-serum level = supposingly no PSA expression of tumor

Design outcomes

Primary

Measure	Time frame
Primary outcome is reached by determination of PSA-serum value on date of the control-examination 4 weeks after a therapy cycle	—

Countries

Germany

Contacts

Public ContactJuri Ruf

Klinik für Nuklearmedizin

juri.ruf@unklinik-freiburg.de0761-27039160

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026